New narcolepsy pill aims to banish daytime drowsiness

NCT ID NCT07502443

Recruiting now Symptom relief Sponsor: Alkermes, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests a new tablet called ALKS 2680 to see if it can reduce daytime sleepiness in adults with narcolepsy type 2. About 176 participants will receive either the study drug or a placebo for 12 weeks. The main goal is to measure how well they can stay awake using a standard wakefulness test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disorders of Excessive Somnolence narcolepsy without cataplexy sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NARCOLEPSY TYPE 2

Contacts and locations

Locations

Alkermes Investigational Site
RECRUITING

Cincinnati, Ohio, 45245, United States
Alkermes Investigational Site
RECRUITING

Wyomissing, Pennsylvania, 19610, United States
Alkermes Investigational Site
RECRUITING

Columbia, South Carolina, 29201, United States
Alkermes Investigational Site
RECRUITING

Austin, Texas, 78731, United States
Alkermes Investigational Site
RECRUITING

San Antonio, Texas, 78229, United States
Alkermes Investigational Site
RECRUITING

Sugar Land, Texas, 77478, United States
Alkermes Investigational Site
RECRUITING

Namur, Belgium
Alkermes Investigational Site
RECRUITING

Markham, Ontario, L3R 1A3, Canada
Alkermes Investigational Site
RECRUITING

Toronto, Ontario, M5S 3A3, Canada
Alkermes Investigational Site
RECRUITING

Bordeaux, France
Alkermes Investigational Site
RECRUITING

Lyon, France
Alkermes Investigational Site
RECRUITING

Montpellier, France
Alkermes Investigational Site
RECRUITING

Bologna, Italy
Alkermes Investigational Site
RECRUITING

Heeze, Netherlands
Alkermes Investigational Site
RECRUITING

Barcelona, Spain
Alkermes Investigational Site
RECRUITING

Cullman, Alabama, 35055, United States
Alkermes Investigational Site
RECRUITING

Los Angeles, California, 90025, United States
Alkermes Investigational Site
RECRUITING

Boulder, Colorado, 80301, United States
Alkermes Investigational Site
RECRUITING

Brandon, Florida, 33511, United States
Alkermes Investigational Site
RECRUITING

Maimi, Florida, 33176, United States
Alkermes Investigational Site
RECRUITING

Winter Park, Florida, 32789, United States
Alkermes Investigational Site
RECRUITING

Macon, Georgia, 31210, United States
Alkermes Investigational Site
RECRUITING

Stockbridge, Georgia, 30281, United States
Alkermes Investigational Site
RECRUITING

Kansas City, Kansas, 66160, United States
Alkermes Investigational Site
RECRUITING

Newton, Massachusetts, 02459, United States
Alkermes Investigational Site
NOT_YET_RECRUITING

Lansing, Michigan, 48911, United States
Alkermes Investigational Site
RECRUITING

Charlotte, North Carolina, 28210, United States
Alkermes Investigational Site
RECRUITING

Huntersville, North Carolina, 28078, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.